Related Experiment Video

Updated: Apr 16, 2026

Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle
09:35

Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle

Published on: February 1, 2017

14.1K

Hepatitis B virus infection in children

Haruki Komatsu1, Ayano Inui

  • 1Department of Pediatrics, Toho University, Sakura Medical Center, 564-1 Shimoshizu Sakura, Chiba, 285-8741, Japan.

Expert Review of Anti-Infective Therapy
|March 1, 2015
PubMed

Insights

Hepatitis B vaccination has reduced childhood infections globally, but some children remain vulnerable. Research is ongoing to determine optimal antiviral treatment strategies for chronic hepatitis B in pediatric populations.

Area of Science:

  • Pediatric Infectious Diseases
  • Hepatology
  • Vaccinology

Background:

  • Hepatitis B vaccination is standard in childhood programs, decreasing HBsAg prevalence.
  • Gaps in vaccine access persist in certain regions, leaving some children susceptible.
  • Chronic hepatitis B infection in children can lead to severe outcomes like cirrhosis and liver cancer.

Purpose of the Study:

  • To review the clinical outcomes of chronic hepatitis B virus infection in children.
  • To discuss the controversies surrounding treatment initiation and drug selection for pediatric hepatitis B.
  • To highlight the need for more research on hepatitis B pathogenesis and antiviral efficacy in children.

Main Methods:

  • Review of long-term follow-up studies on childhood hepatitis B infection.
  • Analysis of current data on antiviral drug approvals and usage in pediatric populations.
  • Examination of strategies for preventing mother-to-child transmission of hepatitis B virus.

Main Results:

  • While vaccination has decreased HBsAg prevalence, chronic infection still occurs in some children.
  • A subset of chronically infected children face risks of liver cirrhosis and hepatocellular carcinoma.
  • Data on the efficacy and optimal treatment protocols for pediatric hepatitis B are limited compared to adults.

Conclusions:

  • Despite widespread vaccination, challenges remain in preventing and treating hepatitis B in children.
  • Further research is crucial to establish evidence-based guidelines for antiviral therapy in pediatric hepatitis B.
  • Antiviral interventions, including in pregnant women, are vital for reducing transmission and managing infection.

Keywords:
HBVHBeAgHBsAgIFNchronic hepatitiscirrhosishepatocellular carcinomamother to childnucleoside analoguevaccine

More Related Videos

Modeling Hepatitis B Virus Infection in Non-Hepatic 293T-NE-3NRs Cells09:02

Modeling Hepatitis B Virus Infection in Non-Hepatic 293T-NE-3NRs Cells

Published on: June 5, 2020

8.0K
A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target11:34

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

2.8K

Related Concept Videos

Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver.
63
Cytomegalovirus Disease01:27

Cytomegalovirus Disease

Cytomegalovirus (CMV) disease is caused by human cytomegalovirus, a double-stranded DNA virus of the Herpesviridae family. While primary CMV infection is often asymptomatic in immunocompetent individuals, the virus can cause severe disease in neonates and immunocompromised patients. CMV is the most common cause of congenital viral infection in the United States, and a major pathogen in solid organ and hematopoietic stem cell transplant recipients.CMV is transmitted via bodily fluids, sexual...
62
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
362
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
391
Immunodeficiency Diseases01:25

Immunodeficiency Diseases

Immunodeficiency disorders are conditions in which the immune system's ability to fight infectious disease and cancer is compromised or entirely absent. The immune system comprises a complex network of cells, tissues, and organs that work together to protect the body from potentially harmful invaders. When this system is deficient or not functioning properly, it leaves the body susceptible to infections, diseases, or other complications.
There are three main causes of immunodeficiency...
3.6K
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
863